FDA Grants Accelerated Approval for Alzheimer’s Drug
Earlier today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments. Accelerated approval can be based on the drug’s effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with a required post-approval trial to verify that the drug provides the expected clinical benefit.
The coalition is putting together a question and answer document on aducanumab to answer frequently asked questions about the treatment. For more information on the approval, please visit the FDA’s official announcement here.